ASCO: Survival Up With Ribociclib in Advanced Breast Cancer

TUESDAY, June 4, 2019 -- For premenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer, adding ribociclib to standard-of-care endocrine therapy is associated with improved overall...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news